Published in Am Soc Clin Oncol Educ Book on January 01, 2015
Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | NCT01266460
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | NCT02280811
GSK1120212+GSK2141795 for Cervical Cancer | NCT01958112
ADXS11-001 High Dose HPV+ Cervical Cancer | NCT02164461
Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer (TACO) | NCT01561586
Phase II Study of Pazopanib and Topotecan in Cervical Cancer | NCT02348398
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA (2004) 14.05
Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med (1999) 11.58
Tumor angiogenesis. N Engl J Med (2008) 11.30
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer (2008) 6.96
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Public attitudes toward participation in cancer clinical trials. J Clin Oncol (2003) 4.41
Race, medical researcher distrust, perceived harm, and willingness to participate in cardiovascular prevention trials. Medicine (Baltimore) (2008) 4.14
Clinical trial participation. Viewpoints from racial/ethnic groups. Cancer (1994) 4.09
Cervical cancer. Lancet (2003) 4.05
Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 4.01
Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol (2008) 3.90
Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol (2008) 3.45
Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys (2011) 3.01
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol (2009) 2.82
Landscape of genomic alterations in cervical carcinomas. Nature (2013) 2.61
Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet (2009) 2.43
Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer (2003) 2.27
Quality of life in long-term cervical cancer survivors. Gynecol Oncol (2005) 2.22
Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol (2005) 2.17
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol (2010) 2.16
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol (2005) 2.10
Ultrasound guided conformal brachytherapy of cervix cancer: survival, patterns of failure, and late complications. J Gynecol Oncol (2014) 2.08
Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol (2012) 1.98
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res (2007) 1.96
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (2009) 1.87
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol (2007) 1.83
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol (2011) 1.71
Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr (2005) 1.70
Sexual morbidity in very long term survivors of vaginal and cervical cancer: a comparison to national norms. Gynecol Oncol (2007) 1.63
Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Res (1994) 1.63
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53
Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol (1999) 1.53
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer (2013) 1.52
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial. Gynecol Oncol (2009) 1.50
Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin Cancer Res (1999) 1.49
Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine (2009) 1.45
Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2012) 1.42
Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist (2002) 1.41
Health-related quality of life in cervical cancer survivors: a population-based survey. Int J Radiat Oncol Biol Phys (2008) 1.36
A systematic review of sexual concerns reported by gynecological cancer survivors. Gynecol Oncol (2011) 1.35
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol (2009) 1.32
Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res (2007) 1.32
Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer (2006) 1.32
PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol (2012) 1.27
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. Clin Cancer Res (2008) 1.23
Quality of life and mental health in cervical and endometrial cancer survivors. Gynecol Oncol (2005) 1.19
Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses. Virology (2009) 1.18
Involving American Indians and medically underserved rural populations in cancer clinical trials. Clin Trials (2009) 1.16
Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer. Cancer (2000) 1.14
Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. Int J Gynecol Cancer (2009) 1.13
A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4(+)FOXP3(+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol (2010) 1.13
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications. Semin Oncol (2010) 1.11
Identification of a 6-cM minimal deletion at 11q23.1-23.2 and exclusion of PPP2R1B gene as a deletion target in cervical cancer. Cancer Res (2000) 1.11
Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells. Cancer Res (1998) 1.11
Psychosocial intervention effects on adaptation, disease course and biobehavioral processes in cancer. Brain Behav Immun (2012) 1.10
The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging (2008) 1.10
The impact of cervical cancer on quality of life--the components and means for management. Gynecol Oncol (2007) 1.09
Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer (2005) 1.08
Cervical cancer. J Natl Compr Canc Netw (2010) 1.07
Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. Int J Gynecol Cancer (2006) 1.07
Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer (2000) 1.07
Host immune responses to cervical cancer. Curr Opin Obstet Gynecol (2009) 1.06
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys (2012) 1.06
Lymph node assessment in cervical cancer: prognostic and therapeutic implications. J Surg Oncol (2009) 1.05
Patient reported late effects of gynecological cancer treatment. Gynecol Oncol (2011) 1.03
Psychosocial stress and inflammation in cancer. Brain Behav Immun (2012) 1.02
Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother (2012) 1.00
A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer (2013) 1.00
A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol (2009) 1.00
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol (2013) 0.99
RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys (2014) 0.97
Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. BMC Cancer (2013) 0.96
Different angiogenic pathways in human cervical cancers. Gynecol Oncol (1998) 0.96
Significance of tumor volume and corpus uteri invasion in cervical cancer patients treated by radiotherapy. Int J Gynecol Cancer (2006) 0.96
Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.95
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 0.94
Cervical cancer survivorship in a population based sample. Gynecol Oncol (2008) 0.94
Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys (2002) 0.92
The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med (2009) 0.92
Surviving cervical cancer: does health-related quality of life influence survival? Gynecol Oncol (2010) 0.92
State of the science in cervical cancer: where we are today and where we need to go. Cancer (2014) 0.91
Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol Cancer (2012) 0.91
Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett (2002) 0.91
Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer (2003) 0.91
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer (2009) 0.91
Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol (2006) 0.90
Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials. Gynecol Oncol (2014) 0.90
Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer (1999) 0.89
The impact of cervical cancer on quality of life: a personal account. Gynecol Oncol (2008) 0.89